Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

First International Summit on Interventional Pharmacoeconomics

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Opportunities to Optimize Cancer Policies Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Varsha Gandhi, PhD, on Ibrutinib

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Nov

Today In Oncology

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Opportunities to Optimize Cancer Policies Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Varsha Gandhi, PhD, on Ibrutinib

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Breast Cancer Risk and Disease-Causing Genetic Mutations in Women Older Than 65

Prediagnosis and Postdiagnosis Physical Activity and Survival in Endometrial Cancer

Should Patients With a Complete Response to Neoadjuvant Chemoradiation for Rectal Cancer Also Undergo Surgery

Intermittent Dosing Schedules of RAF/MEK Inhibitor in RAS/RAF-Mutant Solid Tumors and Multiple Myeloma

Study Finds Universal Genetic Testing Uncovers More Inherited Mutations vs Guideline-Based Genetic Testing